The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVIII.a

BAL: An excess proportion of lymphocytes

Publications

Marvisi M, Ramponi S, Balzarini L, Mancini C

A "crazy paving" pattern on CT scan in a patient treated with Pembrolizumab.

Current drug safety 2019 Mar 11;; — 2019 Mar 11

Oda K, Kato K, Nakamura M, Jotatsu T, Noguchi S, Kawanami T, Kido T, Yatera K

Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab.

Lung cancer (Amsterdam, Netherlands) 2018 04;118;171-172 — 2018 04 — 171-172

Leroy V, Templier C, Faivre JB, Scherpereel A, Fournier C, Mortier L, Wemeau-Stervinou L

Pembrolizumab-induced pneumonitis.

ERJ open research 2017 Apr;3; — 2017 Apr

Fragkou P, Souli M, Theochari M, Kontopoulou C, Loukides S, Koumarianou A

A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab.

Drug target insights 2016;10;9-12 — 2016 — 9-12